Brief: RenovoRx, Imugene Announce Collaboration To Deliver Oncolytic Virus Therapy
20/07/2023 13:19
July 20 (Reuters) - Imugene Ltd IMU.AX :
* RENOVORX AND IMUGENE ANNOUNCE COLLABORATION TO DELIVER
ONCOLYTIC
VIRUS THERAPY USING PROPRIETARY TRANS-ARTERIAL MICRO-PERFUSION
(TAMP™) PLATFORM
* RENOVORX INC- COLLABORATION WILL EXPLORE TRANS-ARTERIAL
DELIVERY
OF IMUGENE'S CF33 ONCOLYTIC VIRUS UTILIZING RENOVORX'S TAMP
THERAPY PLATFORM.
Source text for Eikon: ID:nBw8rk6tca
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies